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Abstract
Background Fibromatosis is an aggressive fibrous tumor of
unknown etiology that is, in some cases, lethal. Until now,
there has been no particular classification for the head and
neck. Therefore, the aim of the present study was to review
the current literature in order to propose a new classification
for future studies.
Methods An evidence-based literature review was conducted
from the last 40 years regarding aggressive fibromatosis in the
head and neck. Studies that summarized patients’ data without
including individual data were excluded.
Results Between 1968 and 2008, 179 cases with aggressive
fibromatosis of the head and neck were published. The
male to female ratio was 91 to 82 with a mean age of
16.87 years, and 57.32% of the described cases that
involved the head and neck were found in patients under
11 years. The most common localization was the mandible,
followed by the neck. All together, 143 patients were
followed up, and in 43 (30.07%), a recurrence was seen.
Conclusion No clear prognostic factors for recurrence (age,
sex, or localization) were observed. A new classification
with regard to hormone receptors and bone involvement
could improve the understanding of risk factors and thereby
assist in future studies.
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Introduction
Fibromatosis is an aggressive fibrous tumor that is
characterized by local invasiveness and a high recurrence
rate. Erosion and invasion of the bone may occur, but
metastasizing has not been described. This entity belongs
to a group of fibrous proliferative disorders including
plantar fibromatosis (Dupuytren), penile fibromatosis
(Peyronie disease), palmar fibromatosis (Ledderhose
disease), abdominal fibromatosis, and intra-abdominal
fibromatosis [1].
Only 12% of extra-abdominal fibromatoses arise in
the head and neck region. One of the largest series of
head and neck involvements was published by Conley
et al. in 1966 [2]. This tumor seems to be more
aggressive in the head and neck than those arising from
the abdominal wall. One reason could be the restricted
anatomy, with its vital vascular, neural structures contrib-
uting to the severity of the clinical manifestation, as well
as to the recurrence rate following attempts at surgical
removal.
However, two main classifications for fibromatosis have
been introduced, one by Allen in 1977 [3] (Table 1) and
one by Enziger and Weiss in 1995 [1], which is a
classification with two subdivisions: superficial (fascial)
and deep (musculoaponeurotic) fibromatosis.
However, no classification has been published so far
dealing with fibromatosis of the head and neck.
Therefore, the aim of the present study was to
determine the common features of and prognostic
factors for this uncommon, but aggressive, disease in
the head and neck, with the intent to propose a new
classification.
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Material and method
For the literature review, a search strategy was devised in
consultation with a senior librarian at the University of
Zurich in which electronic databases (Medline and
Cochrane) were searched using a set of predetermined
keywords. The search strategy was initially developed and
implemented for PubMed but was revised appropriately to
suit the other databases. No restriction was placed on the
language of publication. Studies that summarized patients’
data without including individual data were excluded.
The citations retrieved from each database were exported
into EndNote, which is bibliometric management software.
Duplicates were discarded. The titles and abstracts were
screened, and hard copies of all potentially relevant articles
were retrieved. Their reference lists were manually searched
for any related articles.
Results
Between 1968 and 2008, 179 cases were published dealing
with aggressive fibromatosis of the head and neck. The
male/female ratio was almost 1:1 (91–82) with a mean age
of 16.87 years (Fig. 1). However, 57.32% of the described
cases with head and neck involvement were found in
patients under 11 years of age. The most common
localization was the mandible, followed by the neck, but
an exact localization is difficult to define because of the
differentiation in the case reports between mandible,
submandibular, and neck (Fig. 2).
Concerning therapy, several strategies have been
reported (Fig. 3). In six cases, tamoxifen therapy—because
of positive hormone receptors—has been admitted.
Concerning recurrence rate, an exact comparison is impos-
sible due to different follow-up times.
A total of 143 patients were followed up, and in 43 cases
(30.07%), a recurrence was seen (Fig. 4), but no correlation
with localization was detected. In one patient, a transfor-
mation into a fibrosarcoma occurred [4], and another
publication discussed the development of a fibrosarcoma
[5]. Invasion of nerves and blood vessels was never
reported.
Discussion
The pathogenesis of these nonencapsulated lesions is still
unknown; they take their origin from fascia, periosteum, or
musculocaponeuroses [6]. Desmoid fibromatosis, also
called aggressive fibromatosis and musculoaponeurotic
fibromatosis, can be associated with polyposis coli, colonic
adenocarcinoma, epidermoid cysts, and osteomas; in a very
few cases, it can be fatal [3].
Some authors have implicated trauma [7] or genetic and
endocrine factors in the development of these lesions [8].
The terminology was first defined by Stout in 1954 [9].
Several terms have been used in the literature in order to
describe this entity: desmoid tumor, desmona, and non-
metastasizing fibrosarcoma [10].
Differential diagnoses include fibroma, keloid, fibroma-
tosis, fibrosarcoma, and myositis proliferans. Concerning
myositis proliferans, both diseases present infiltration of
muscle and in the ligament tissue, draught of fish pattern,
but myositis proliferans grows faster, presenting more
mitoses, and contrary to aggressive fibromatosis, a pleo-
morphic cell overview [5]. Table 2 presents an overview of
the immunohistochemical profiles of benign spindle cell
lesions.
Because of the aggressive growth pattern and high cell
concentration, this classification is based on differentiation
between children and adults, but our review does not
support the conclusion that in children, the tumor is more
aggressive than in adults.
Concerning incidence, only very few data are available.
The estimated incidence in the general population is 2–4/
1,000,000/year [11]. No significant racial or ethnic distri-
bution is reported. In children, a fibromatosis incidence of
2.2% is mentioned [12]. A manifestation in the head and
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Table 1 Classification by Allen [3]
Classification by Allen [3]
Extra-abdominal
Abdominal wall desmoids
Intra-abdominal desmoids
Multiple desmoids
Desmoids in Gardner`s syndrome
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neck is reported in 12% of all cases [7]. Inguinal
fibroblastic and myofibroblastic tumors are present in about
12% of soft tissue tumors, and 76% are benign. In 27% of
cases, the topography site is the head and side of the neck,
and 71% occur in the first decade of life [13]. Other authors
estimate that 34% of all fibromatoses occur in the head and
neck [14]. The mastoid region is described by some authors
as one of the most common localizations in the head and
neck [7, 15]. This was not supported by our review, in
which the preferred sites in the head and neck region were
mandible and neck.
Tumors in the oral cavity and paranasal sinus seem to be
more aggressive and lethal than those on other sides [7].
This fact emphasizes the need for a separate classification
for this entity. Lakhan et al. reported that approximately
0.03% of all neoplasms are desmoid tumors and that they
constitute less than 3% of all soft tissue tumors [16]. An
identification of clonal chromosomal changes has been
reported in a significant fraction of cases [17]. Trisomie
8 and 20 in desmoid tumors have been discussed [18].
Concerning therapy options, several proposals have been
reported (Table 3), but most authors advocate a direct
surgical approach; in cases of unresectable tumors because
of anatomical limits in order to reduce tumor size, some
authors have suggested chemotherapy. Concerning radio-
therapy, only very few results have been published. Spear et
al. and Posner et al. showed in their studies that
radiotherapy, added to surgery with residual disease or to
surgery for recurrent disease, led to significant improve-
ment in local control [19, 20], but there is still controversy
concerning the dose, particularly in growing children because
of possible long-time complications. In their study, Spear et al.
reported a difference in local control for doses <50 Gy (36%
versus >50 Gy (88%)) [19]. Chalmers et al. implied some
interesting points concerning the effect of radiotherapy
without surgery [21]. On the one hand, surgery and trauma
can provide an impetus for tumor development; therefore,
avoidance of surgery with only radiotherapy could lead to
improvement. On the other hand, radiotherapy itself could
change the tumor behavior. If surgery is performed,
controversy still surrounds the recommendation for surgical
margins: Plukker et al. advocate 3-cm margins in adults [22].
Recurrence is described more frequently in young patients
[3], but our results do not support this theory.
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One concern in radiotherapy for children is its negative
influence on growth, leading to possible deformities.
The possibility of non-surgical treatment is interesting in
particular for tumors localized in anatomically difficult
structures that need to be preserved as much as possible,
e. g., the sinuses. On the other hand, one has to keep in
mind the potential toxicity associated with the systemic
application of chemotherapy. Surgical resection that results
in tumor-free margins and a function-preserving approach
are the goals.
Therefore, some authors advocate an estrogen receptor
test on the tissue sample in order to provide tamoxifen
therapy because spontaneous regression has been observed
in the menarche and menophase [23]. One reason seems to
be the ability of antiestrogen compounds in vitro to
stimulate the secretion of transforming growth factor beta
(TGFb) by stromal fibroblasts, leading to inhibiting the
growth of surrounding epithelial cells. Benson and Baum
[24] hypothesize that in aggressive fibromatosis, the tissue
may consist of immature fibroblasts with a fetal phenotype
characterized by a negative growth response to TGFb, but
the short and long-term toxicity to children (with regard to
growth, puberty) resulting from this hormonal therapy must
be considered. In women that have been treated with
tamoxifen for breast cancer, an increased probability for
incidence of endometrial carcinomas is discussed.
In recent times, some authors have advocated another
therapy option with interferon alpha for disease stabiliza-
tion because IFN type I seems to be a positive regulator of
neoplastic growth [25, 26]. Another therapy option could
be tyrosine kinase inhibitor imatinib due to tumor expres-
sion of activated receptor tyrosine kinase c-kit and/or
platelet-derived growth factor receptor alpha [27].
Controversy also surrounds radiotherapy. Some authors
advocate this therapy option [28], whereas others doubt the
effect, in particular at high doses because of side effects.
The problem concerning all these therapy options seems to
be the lack of experience in using them for head and neck
fibromatosis; it seems to be more common to use these
strategies in intra-abdominal manifestations where resec-
tions can be difficult because of the diffuse infiltration.
Some authors prefer a radical neck dissection for all neck
fibromatoses in order to reduce recurrence rates by 33%
through aggressive surgery [29], but since aggressive
fibromatosis do not metastasize and because the recurrence
rate is higher in young patients, one should be careful with
the indication for a radical neck dissection.
The only factor for recurrence-free follow-up seems to
be negative margins [16, 30, 31]. On the other hand, some
authors claim that recurrence seems to be independent of
the margin status [32, 33], and a margin of less than 1 mm
did not adversely affect outcome when compared with more
generous margins.
Our results show that the probability for recurrence
seems to be independent of age or localization (Fig. 5).
Surgery
Chemotherapy (vincristine/actinomycin, cyclophosphamide, or methotrexate/vinblastine) [37]
Hyperthermia
Hormone therapy (antiestrogen) [38]
NSAR therapy [38]
Radiation
Selective tyrosine kinase inhibitor and alpha-interferon [39]
Combined therapy
Table 3 Overview of different
therapy options
Table 2 Immunohistochemical profiles of fibromatosis and other
benign spindle cell lesions [35, 36]
Vimentin Actin S100 Desmin
Fibromatosis + − − −
Infantile myofibromatosis + + − −
Neurofibroma + − + −
Leiomyoma + + − +
Nodular fasciitis + + − −
Fibrous histiocytoma + +/− − − 0
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Other researchers have included as prognostic factors an
age of less than 18 years, recurrent disease, and treatment
with surgery alone [19]. Concerning localization, Scougall
et al. [34] showed that there are no differences in the
outcome between children and adults.
Because of missing correlations among the localization,
age, and recurrence rates, we propose a new classification
for this entity in order to evaluate further cases (Fig. 6).
Conclusion
No clear prognostic factors for recurrence (age, sex, or
localization) were observed. A new classification with
regard to hormone receptors and bone involvement could
improve the understanding of risk factors clinically and for
future studies.
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